CD38 and lung carcinoma: Given this and our prior work17–20, it was hypothesized that an RARα antagonist (IRX6696) would cooperate with anti-PD-L1 therapy to elicit an anti-tumor response to a previously resistant syngeneic lung cancer by reducing CD38 expression and thereby conferring anti-neoplastic effects.